TY - JOUR
T1 - A polyurethane vascular access graft and a hybrid polytetrafluoroethylene graft as an arteriovenous fistula for hemodialysis
T2 - Comparison with an expanded polytetrafluoroethylene graft
AU - Matsuda, Hiroaki
AU - Miyazaki, Masashi
AU - Oka, Yoshinari
AU - Nakao, Atsunori
AU - Choda, Yasuhiro
AU - Kokumai, Yoshiaki
AU - Kunitomo, Keiichi
AU - Tanaka, Noriaki
PY - 2003/8/1
Y1 - 2003/8/1
N2 - Aim: We evaluated a polyurethane vascular access graft (TVAG), a hybrid polytetrafluoroethylene graft (hPTFEG), and an expanded polytetrafluoroethylene graft (ePTFEG) for postoperative complications and graft patency in their use as prosthetic devices of vascular access for hemodialysis. Methods: Between August 1993 and October 2001, we treated 200 patients in whom A-V fistulas were placed by the same surgeon. These were divided into the following four groups according to the type of blood access: 27 cases of ePTFEG, 23 cases of TVAG, 22 cases of hPTFEG, and 128 cases of an autogenous A-V fistula. We calculated the cumulative patency rates by the Kaplan-Meier method, including primary (problem-free) and secondary (revised or functional) patency rates. Results: The hPTFEG group experienced few thromboses. The absence of perigraft edema in the TVAG group permitted the early use of the TVAG within a few postoperative days for hemodialysis. Among the three graft groups, the primary patency was the best in the hPTFEG group (94.7% at 1 year and 86.1% at 2 years), with a significant difference versus the ePTFEG group. In regard to secondary patency, hPTFEG had an excellent patency of 100% at 1 year and 90.9% at 2 years, and TVAG had a comparable patency with that of ePTFEG. Conclusion: The hPTFEG was considered superior to ePTFEG in terms of being complication-free and had the excellent 2 year secondary patency of 90.9%. TVAG, with a patency equal to that of ePTFEG, could be used immediately after implantation due to the absence of limb edema.
AB - Aim: We evaluated a polyurethane vascular access graft (TVAG), a hybrid polytetrafluoroethylene graft (hPTFEG), and an expanded polytetrafluoroethylene graft (ePTFEG) for postoperative complications and graft patency in their use as prosthetic devices of vascular access for hemodialysis. Methods: Between August 1993 and October 2001, we treated 200 patients in whom A-V fistulas were placed by the same surgeon. These were divided into the following four groups according to the type of blood access: 27 cases of ePTFEG, 23 cases of TVAG, 22 cases of hPTFEG, and 128 cases of an autogenous A-V fistula. We calculated the cumulative patency rates by the Kaplan-Meier method, including primary (problem-free) and secondary (revised or functional) patency rates. Results: The hPTFEG group experienced few thromboses. The absence of perigraft edema in the TVAG group permitted the early use of the TVAG within a few postoperative days for hemodialysis. Among the three graft groups, the primary patency was the best in the hPTFEG group (94.7% at 1 year and 86.1% at 2 years), with a significant difference versus the ePTFEG group. In regard to secondary patency, hPTFEG had an excellent patency of 100% at 1 year and 90.9% at 2 years, and TVAG had a comparable patency with that of ePTFEG. Conclusion: The hPTFEG was considered superior to ePTFEG in terms of being complication-free and had the excellent 2 year secondary patency of 90.9%. TVAG, with a patency equal to that of ePTFEG, could be used immediately after implantation due to the absence of limb edema.
KW - Blood access
KW - Expanded polytetrafluoroethylene graft
KW - Graft patency
KW - Hemodialysis
KW - Hybrid polytetrafluoroethylene graft
KW - Polyurethane graft
UR - http://www.scopus.com/inward/record.url?scp=0041328208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041328208&partnerID=8YFLogxK
U2 - 10.1046/j.1525-1594.2003.07031.x
DO - 10.1046/j.1525-1594.2003.07031.x
M3 - Article
C2 - 12911347
AN - SCOPUS:0041328208
SN - 0160-564X
VL - 27
SP - 722
EP - 727
JO - Artificial Organs
JF - Artificial Organs
IS - 8
ER -